Asthma - Pipeline Review, H2 2013


Naperville, IL -- (SBWIRE) -- 09/06/2013 -- Reportstack, provider of premium market research reports announces the addition of Asthma - Pipeline Review, H2 2013 market report to its offering
Asthma - Pipeline Review, H2 2013


, 'Asthma - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Asthma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Asthma. Asthma - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- A snapshot of the global therapeutic scenario for Asthma.
- A review of the Asthma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Asthma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Asthma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Asthma pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

Alcon, Inc.
Johnson & Johnson
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Kyowa Hakko Kirin Co., Ltd.
EpiGenesis Pharmaceuticals, Inc.
Amgen Inc.
AstraZeneca PLC
GlaxoSmithKline plc
Genentech, Inc.
Biotec Pharmacon ASA
MedImmune LLC
Daiichi Sankyo Company, Ltd
Merck & Co., Inc.
Nissan Chemical Industries, Ltd.
Dainippon Sumitomo Pharma Co., Ltd.
Infinity Pharmaceuticals, Inc.
SkyePharma PLC
Vectura Group plc
BioLineRx, Ltd.
Novartis AG
Isotechnika Pharma Inc.
Actelion Ltd
ALK-Abello A/S
ASKA Pharmaceutical Co., Ltd
Astellas Pharma Inc.
Chiesi Farmaceutici SpA
Dong-A Pharmaceutical Co., Ltd.
Glenmark Pharmaceuticals Ltd.
Kissei Pharmaceutical Co., Ltd.
Mitsubishi Tanabe Pharma Corporation
Ono Pharmaceutical Co., Ltd.
Orion Corporation
Pfizer Inc.
Rigel Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Limited
Zambon Group S.p.A.
Sun Pharmaceutical Industries Limited
OPKO Health, Inc.
iCo Therapeutics Inc.
Antisense Therapeutics Limited
Idera Pharmaceuticals, Inc.
Almirall, S.A.
Basilea Pharmaceutica Ltd.
Mesoblast Ltd
Orchid Chemicals & Pharmaceuticals Ltd
Palatin Technologies, Inc.
Pharmaxis Ltd.
Portola Pharmaceuticals, Inc.
CSL Limited
Cytokinetics, Inc
Yungjin Pharm Ind. Co., Ltd.
Yuhan Corporation
WhanIn Pharmaceutical Co., Ltd.
Regeneron Pharmaceuticals, Inc.
NeoStem, Inc.
Array BioPharma Inc.
Dynavax Technologies Corporation
Stallergenes S.A.
Cytos Biotechnology AG
Ahn-Gook Pharmaceutical Co., Ltd.
Neurim Pharmaceuticals (1991) Ltd.
Synairgen plc
Panacea Biotec Limited
Orexo AB
Verona Pharma Plc
Morphotek, Inc.
Marinomed Biotechnologie GmbH
Alba Therapeutics Corporation
Allergopharma Joachim Ganzer KG
Immupharma Plc
Palau Pharma S.A
Farmacija d.o.o. Tuzla
Pieris AG
Respiratorius AB
Aquinox Pharmaceuticals Inc.
Proteologics, Inc.
Funxional Therapeutics Ltd
ZaBeCor Pharmaceuticals
Nostrum Pharmaceuticals, LLC
Promedior, Inc.
Pulmatrix, Inc.
Axikin Pharmaceuticals, Inc.
Five Prime Therapeutics, Inc.
MSM Protein Technologies, Inc.
Indus Biotech Private Limited
AIM Therapeutics Inc.
Hydra Biosciences, Inc.
Theraclone Sciences, Inc.
Vantia Therapeutics
Biotica Technology Ltd
Monosol Rx, LLC
NKT Therapeutics, Inc.
Omeros Corporation
Transtech Pharma, Inc.
Xencor, Inc.
Cornerstone Therapeutics Inc.
Targacept, Inc.
BaroFold, Inc.
Cellceutix Corporation
CBio Limited
KaloBios Pharmaceuticals, Inc.
AB Science
Adamis Pharmaceuticals Corporation
Asmacure Limited
Lycera Corp.
iCeutica, Inc.
N30 Pharmaceuticals
GlycoMar Limited
Biocure pharm
Clarassance, Inc.

To view the table of contents for this market research report please visit